A detailed history of Zurcher Kantonalbank (Zurich Cantonalbank) transactions in Viking Therapeutics, Inc. stock. As of the latest transaction made, Zurcher Kantonalbank (Zurich Cantonalbank) holds 22,823 shares of VKTX stock, worth $1.2 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
22,823
Previous 22,823 -0.0%
Holding current value
$1.2 Million
Previous $1.44 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 07, 2024

BUY
$49.84 - $70.47 $32,196 - $45,523
646 Added 2.91%
22,823 $1.44 Million
Q2 2024

Jul 29, 2024

BUY
$47.39 - $80.2 $177,949 - $301,151
3,755 Added 20.38%
22,177 $1.18 Million
Q1 2024

Apr 25, 2024

SELL
$17.4 - $94.5 $33,321 - $180,967
-1,915 Reduced 9.42%
18,422 $1.51 Million
Q4 2023

Jan 30, 2024

BUY
$9.24 - $19.64 $34,169 - $72,628
3,698 Added 22.22%
20,337 $378,000
Q3 2023

Oct 25, 2023

BUY
$10.92 - $16.0 $45,165 - $66,176
4,136 Added 33.08%
16,639 $184,000
Q2 2023

Aug 07, 2023

BUY
$14.84 - $24.79 $50,752 - $84,781
3,420 Added 37.65%
12,503 $202,000
Q1 2023

May 08, 2023

BUY
$8.08 - $17.33 $73,390 - $157,408
9,083 New
9,083 $151,000
Q2 2022

Aug 09, 2022

SELL
$2.11 - $3.15 $42,820 - $63,926
-20,294 Closed
0 $0
Q4 2021

Feb 01, 2022

BUY
$4.6 - $6.72 $55,866 - $81,614
12,145 Added 149.04%
20,294 $93,000
Q2 2020

Jul 28, 2020

BUY
$4.35 - $8.08 $18,313 - $34,016
4,210 Added 106.88%
8,149 $59,000
Q4 2018

Jan 25, 2019

BUY
$7.16 - $16.21 $28,203 - $63,851
3,939 New
3,939 $30,000

Others Institutions Holding VKTX

About Viking Therapeutics, Inc.


  • Ticker VKTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,688,496
  • Market Cap $4.03B
  • Description
  • Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...
More about VKTX
Track This Portfolio

Track Zurcher Kantonalbank (Zurich Cantonalbank) Portfolio

Follow Zurcher Kantonalbank (Zurich Cantonalbank) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Zurcher Kantonalbank (Zurich Cantonalbank), based on Form 13F filings with the SEC.

News

Stay updated on Zurcher Kantonalbank (Zurich Cantonalbank) with notifications on news.